ImmunoMet

본문 바로가기


Pipeline

As a leader in cancer metabolism and immunometabolism, ImmunoMet Therapeutics has primarily been developing novel chemical entities blocking critical metabolic events of cancer cells and immunosuppressive cells. Our product candidates are designed to combat cancers by preferentially targeting resistant cancer subpopulation and immunosuppressive cells primarily in combination with the current standard of care therapies. Our development platforms have the potential to treat a broad range of cancer types.


Copyright © ImmunoMet. All rights reserved.